Longer time to PSA failure is thought to be desirable as it may be indicative of time to castrationresistant prostate cancer (CRPC) and may delay initiation of second-line therapy, which includes ...

FIRMAGON (degarelix injection) 80mg and 120mg vials of powder for reconstitution by Ferring Ferring Pharmaceuticals announced the FDA has approved the trade name Firmagon (degarelix injection) for its ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

Firmagon is a brand-name medication that contains the active ingredient degaralix. It’s a synthetic hormone blocker that reduces testosterone production, and it’s approved to treat advanced prostate ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hgtc2g/firmagon) has announced the addition of GlobalData's new report ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

Pooled data from five phase III studies of men with prostate cancer (n = 1,925) confirm that androgen deprivation therapy (ADT) with degarelix, a gonadotropin-releasing hormone antagonist, offers ...

Degarelix, a testosterone lowering drug which is given as a monthly injection under the skin and costs around £1,000 a year, was first approved by the European Medicines Agency in 2009 and was ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

To earn CME related to this news article, click here. January 9, 2009 — The US Food and Drug Administration (FDA) has approved fludarabine phosphate tablets for the treatment of B-cell chronic ...